Skip to main content
SpringerLink
Log in

Multiple Sclerosis: Impact on Functioning of the Blood–Brain Barrier

  • Chapter
  • First Online:
Neuroinflammation and Neurodegeneration

  • 1957 Accesses

Abstract

Proper function of the neurovasculature is required for optimal brain function and preventing neuroinflammation and neurodegeneration. During a large number of neurological disorders, dysfunction of the blood–brain barrier (BBB) is an apparent feature and may significantly contribute to disease progression. In particular, during the neuroinflammatory disorder multiple sclerosis (MS), the function of the BBB is severely hampered and immune cells gain access into the brain, causing neurological deficits. Consequently, transport of compounds, including drugs, may be altered under disease condition.

Within this chapter, we will discuss alterations of the function of the BBB and its consequences in the neuroinflammatory disorder multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938–52.

    CAS  PubMed  Google Scholar 

  2. Frohman EM, Racke KM, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942–55.

    CAS  PubMed  Google Scholar 

  3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112:133–46.

    PubMed  Google Scholar 

  4. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157–69.

    PubMed  Google Scholar 

  5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–11.

    CAS  PubMed  Google Scholar 

  6. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 2004;3(2):104–10.

    CAS  PubMed  Google Scholar 

  7. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727–39.

    PubMed  Google Scholar 

  8. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: updated risks for relatives. Am J Med Genet. 1988;29(3):533–41.

    CAS  PubMed  Google Scholar 

  9. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Grey T. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986;315(26):1638–42.

    CAS  PubMed  Google Scholar 

  10. Kinnunen E, Koskenvuo M, Kaprio J, Aho K. Multiple sclerosis in a nationwide series of twins. Neurology. 1998;37(10):1627–9.

    Google Scholar 

  11. McFarland HF. Twin studies and multiple sclerosis. Ann Neurol. 1992;32(6):722–3.

    CAS  PubMed  Google Scholar 

  12. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D’alfonso S, Blackburn H, Martinelli BF, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Compston A, et al. A genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Moore FG, Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand. 2002;106(2):63–83.

    CAS  PubMed  Google Scholar 

  14. Friedman JE, Lyons MJ, Cu G, Ablashl DV, Whitman JE, Edgar M, Koskiniemi M, Vaheri A, Zabriskie JB. The association of the human herpesvirus-6 and MS. Mult Scler. 1999;5(5):355–62.

    CAS  PubMed  Google Scholar 

  15. Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS. 2001;109(6):401–11.

    CAS  PubMed  Google Scholar 

  16. Ohara Y. Multiple sclerosis and measles virus. Jpn J Infect Dis. 1999;52(5):198–200.

    CAS  PubMed  Google Scholar 

  17. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999;46(1):6–14.

    CAS  PubMed  Google Scholar 

  18. Layh-Schmitt G, Bendl C, Hildt U, Dong-Si T, Juttler E, Schnitzler P, Grond-Ginsbach C, Grau AJ. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann Neurol. 2000;47(5):652–5.

    CAS  PubMed  Google Scholar 

  19. Morre SA, De Groot CJ, Killestein J, Meijer CJ, Polman CH, van Middeldorp JM, van Den Brule AJ. Is Epstein-Barr virus present in the CNS of patients with MS? Neurology. 2001;56(5):692–7.

    CAS  PubMed  Google Scholar 

  20. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, Hankinson SE, Hunter DJ. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001;286(24):3083–8.

    CAS  PubMed  Google Scholar 

  21. Lunemann JD. Epstein-Barr virus in multiple sclerosis: a continuing conundrum. Neurology. 2012;78(1):11–2.

    PubMed  Google Scholar 

  22. Lassmann H. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue–report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011;134(9):2772–8.

    PubMed Central  PubMed  Google Scholar 

  23. Kakalacheva K, Lunemann JD. Environmental triggers of multiple sclerosis. FEBS Lett. 2001;585(23):3724–9.

    Google Scholar 

  24. Fleming J, Fabry Z. The hygiene hypothesis and multiple sclerosis. Ann Neurol. 2007;61:85–9.

    PubMed  Google Scholar 

  25. Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011;233:6–11.

    CAS  PubMed  Google Scholar 

  26. Van der van Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol. 2000;26(1):2–12.

    PubMed  Google Scholar 

  27. Vos CMP, Geurts JJG, Montagne EM, van Haastert ES, van der Valk P, Barkhof F, de Vries HE. Blood-brain barrier alterations in both focal and diffuse abnormalities on post mortem MRI in multiple sclerosis. Neurobiol Dis. 2005;20:953–60.

    CAS  PubMed  Google Scholar 

  28. Kirk J, Plumb J, Mirakhur M, McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol. 2003;201:319–27.

    PubMed  Google Scholar 

  29. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 2002;12:154–69.

    PubMed  Google Scholar 

  30. Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol. 2007;33:86–98.

    CAS  PubMed  Google Scholar 

  31. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Capello E, Mancardi GL, Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol. 2006;65(2):124–41.

    CAS  PubMed  Google Scholar 

  32. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(3):393–9.

    PubMed  Google Scholar 

  33. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278–85.

    CAS  PubMed  Google Scholar 

  34. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48(6):893–901.

    CAS  PubMed  Google Scholar 

  35. Zeinstra E, Wilczak N, De KJ. Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. J Neuroimmunol. 2003;135:166–71.

    CAS  PubMed  Google Scholar 

  36. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007;17(1):38–44.

    PubMed  Google Scholar 

  37. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188–97.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8. Review.

    PubMed  Google Scholar 

  39. Klaver R, De Vries HE, Schenk GJ, Geurts JJ. Grey matter damage in multiple sclerosis: a pathology perspective. Prion. 2013;7(1):66–75.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. van Horssen J, Brink BP, de Vries HE, van der Valk P, Bø L. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol. 2007;66(4):321–8.

    PubMed  Google Scholar 

  41. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9.

    CAS  PubMed  Google Scholar 

  42. Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2012;12(4):371–84.

    CAS  PubMed  Google Scholar 

  43. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.

    CAS  PubMed  Google Scholar 

  44. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25.

    CAS  PubMed  Google Scholar 

  45. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200(5):527–33.

    PubMed Central  Google Scholar 

  46. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

    CAS  PubMed  Google Scholar 

  47. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011;12(64):213–28.

    PubMed Central  PubMed  Google Scholar 

  48. Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep. 2011;11(5):492–7.

    PubMed  Google Scholar 

  49. Baker D, Gerritsen W, Rundle J, Amor S. Critical appraisal of animal models of multiple sclerosis. Mult Scler. 2011;17(6):647–57.

    PubMed  Google Scholar 

  50. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A. 2004;5(101):14599–606.

    Google Scholar 

  51. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2002;38(6):323–35.

    CAS  PubMed  Google Scholar 

  52. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost. 2006;95(1):36–47.

    CAS  PubMed  Google Scholar 

  53. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161(3):653–60.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86–98.

    PubMed Central  PubMed  Google Scholar 

  55. Mahringer A, Ott M, Reimold I, Reichel V, Fricker G. The ABC of the blood-brain barrier – regulation of drug efflux pumps. Curr Pharm Des. 2011;17(26):2762–70.

    CAS  PubMed  Google Scholar 

  56. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv. 2010;10(5):293–304.

    CAS  PubMed  Google Scholar 

  57. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci. 2010;31(6):246–54.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Dermietzel R. Junctions in the central nervous system of the cat. 3. Gap junctions and membrane-associated orthogonal particle complexes (MOPC) in astrocytic membranes. Cell Tissue Res. 1974;149(1):121–35.

    CAS  PubMed  Google Scholar 

  59. Nagelhus EA, Mathiisen TM, Ottersen PO. Aquaporin-4 in the central nervous system: cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience. 2004;129(4):905–13.

    CAS  PubMed  Google Scholar 

  60. Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG. Agrin and microvascular damage in Alzheimer’s disease. Neurobiol Aging. 2000;21(2):349–55.

    CAS  PubMed  Google Scholar 

  61. Arthur FE, Shivers RR, Bowman PD. Astrocyte -mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Brain Res. 1987;433(1):155–9.

    CAS  PubMed  Google Scholar 

  62. Tran ND, Correale J, Schreiber SS, Fisher M. Transforming growth factor-beta mediates astrocyte-specific regulation of brain endothelial anticoagulant factors. Stroke. 1999;30(8):1671–8.

    CAS  PubMed  Google Scholar 

  63. Igarashi Y, Utsumi H, Chiba H, Yamada-Sasamori Y, Tobioka H, Kamimura Y, Furuuchi K, Kokai Y, Nakagawa T, Mori M, Sawada N. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem Biophys Res Commun. 1999;261(1):108–12.

    CAS  PubMed  Google Scholar 

  64. el Hafny B, Bourre JM, Roux F. Synergistic stimulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells. J Cell Physiol. 1996;167(3):451–60.

    PubMed  Google Scholar 

  65. Reuss B, Dono R, Unsicker K. Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. J Neurosci. 2003;23(16):6404–12.

    CAS  PubMed  Google Scholar 

  66. Mizee MR, Wooldrik D, Lakeman KA, van het Hof B, Drexhage JA, Geerts D, Bugiani M, Aronica E, Mebius RE, Prat A, de Vries HE, Reijerkerk A. Retinoic acid induces blood-brain barrier development. J Neurosci. 2013;33(4):1660–71.

    CAS  PubMed  Google Scholar 

  67. Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R, Bouthillier A, Reudelhuber TL, Prat A. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci. 2007;27(34):9032–42.

    CAS  PubMed  Google Scholar 

  68. Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, Terouz S, Sabbagh M, Wosik K, Bourbonnière L, Bernard M, van Horssen J, de Vries HE, Charron F, Prat A. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011;334(6063):1727–17231.

    CAS  PubMed  Google Scholar 

  69. Floris S, Blezer EL, Schreibelt G, Döpp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K, Dijkstra CD, de Vries HE. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain. 2004;127(Pt 3):616–27.

    CAS  PubMed  Google Scholar 

  70. Librizzi L, Mazzetti S, Pastori C, Frigerio S, Salmaggi A, Buccellati C, Di Gennaro A, Folco G, Vitellaro-Zuccarello L, de Curtis M. Activation of cerebral endothelium is required for mononuclear cell recruitment in a novel in vitro model of brain inflammation. Neuroscience. 2006;137(4):1211–9.

    CAS  PubMed  Google Scholar 

  71. Hayashi M, Luo Y, Laning J, Strieter RM, Dorf ME. Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells. J Neuroimmunol. 1995;60(1–2):143–50.

    CAS  PubMed  Google Scholar 

  72. Song L, Pachter JS. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res. 2004;67(1):78–89.

    CAS  PubMed  Google Scholar 

  73. Pan W, Stone KP, Hsuchou H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood-brain barrier function. Curr Pharm Des. 2011;17(33):3729–40.

    CAS  PubMed Central  PubMed  Google Scholar 

  74. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173–5.

    CAS  PubMed  Google Scholar 

  75. Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, Robenek H, Tryggvason K, Song J, Korpos E, Loser K, Beissert S, Georges-Labouesse E, Sorokin LM. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med. 2009;15(5):519–27.

    CAS  PubMed  Google Scholar 

  76. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. 2010;10(10):712–23.

    CAS  PubMed  Google Scholar 

  77. Van der Goes A, Wouters D, Huizinga R, van der Pol SMA, Ronken E, Dijkstra CD, de Vries HE Reactive oxygen species influence monocyte migration across the blood-brain barrier. FASEB J 2001;15:U84–99.

    Google Scholar 

  78. Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD, de Vries HE. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med. 2004;200(12):1667–72.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendrikx EM, Döpp ED, Dijkstra CD, Drukarch B, de Vries HE. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol. 2006;177(4):2630–7.

    CAS  PubMed  Google Scholar 

  80. Kooij G, Mizee MR, van Horssen J, Reijerkerk A, Witte ME, Drexhage JA, van der Pol SM, van het Hof AJ, Scheffer G, Scheper R, Dijkstra CD, van der Valk P, de Vries HE. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain. 2001;134(Pt 2):555–70.

    Google Scholar 

  81. Kooij G, van Horssen J, de Lange EC, Reijerkerk A, van der Pol SM, van Het Hof B, Drexhage J, Vennegoor A, Killestein J, Scheffer G, Oerlemans R, Scheper R, van der Valk P, Dijkstra CD, de Vries HE. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun. 2010;34(4):416–25.

    CAS  PubMed  Google Scholar 

  82. Kooij G, van Horssen J, Bandaru VV, Haughey NJ, de Vries HE. The role of ATP-binding cassette transporters in neuro-inflammation: relevance for bioactive lipids. Front Pharmacol. 2012;3:74.

    PubMed Central  PubMed  Google Scholar 

  83. Quintana A, Müller M, Frausto RF, Ramos R, Getts DR, Sanz E, Hofer MJ, Krauthausen M, King NJ, Hidalgo J, Campbell IL. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2009;183(3):2079–88.

    CAS  PubMed  Google Scholar 

  84. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem. 2006;281(13):8379–88.

    CAS  PubMed  Google Scholar 

  85. Didier N, Romero IA, Créminon C, Wijkhuisen A, Grassi J, Mabondzo A. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem. 2003;86(1):246–54.

    CAS  PubMed  Google Scholar 

  86. Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature. 1997;390(6661):680–3.

    CAS  PubMed  Google Scholar 

  87. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008;45(12):1729–37.

    PubMed  Google Scholar 

  88. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, Smith T. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol. 2008;18(1):52–61.

    PubMed  Google Scholar 

  89. Warth A, Kroger S, Wolburg H. Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol. 2004;107(4):311–6.

    CAS  PubMed  Google Scholar 

  90. Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol. 2007;113(2):187–94.

    CAS  PubMed  Google Scholar 

  91. van Doorn R, Nijland PG, Dekker N, Witte ME, Lopes-Pinheiro MA, van het Hof B, Kooij G, Reijerkerk A, Dijkstra C, van der Valk P, van Horssen J, de Vries HE. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 2012;124(3):397–410.

    CAS  PubMed  Google Scholar 

  92. Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, Lakeman K, Dijkstra CD, Van Der Valk P, Reijerkerk A, Alewijnse AE, Peters SL, De Vries HE. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58(12):1465–76.

    PubMed  Google Scholar 

  93. Lassmann H. Targeting intracerebral inflammation in multiple sclerosis: is it feasible? Acta Neuropathol. 2012;124(3):395–6.

    PubMed  Google Scholar 

  94. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B. Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol. 2011;37(1):24–39.

    CAS  PubMed  Google Scholar 

  95. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623–35.

    CAS  PubMed  Google Scholar 

  96. Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B. T-cell trafficking in the central nervous system. Immunol Rev. 2012;248(1):216–27.

    PubMed  Google Scholar 

  97. Seigneuret M, Delaguillaumie A, Lagaudrière-Gesbert C, Conjeaud H. Structure of the tetraspanin main extracellular domain. A partially conserved fold with a structurally variable domain insertion. J Biol Chem. 2001;276(43):40055–64.

    CAS  PubMed  Google Scholar 

  98. Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol. 2005;5(2):136–48.

    CAS  PubMed  Google Scholar 

  99. Hemler ME. Specific tetraspanin functions. J Cell Biol. 2001;155(7):1103–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6(10):801–11.

    CAS  PubMed  Google Scholar 

  101. Barreiro O, Yáñez-Mó M, Sala-Valdés M, Gutiérrez-López MD, Ovalle S, Higginbottom A, Monk PN, Cabañas C, Sánchez-Madrid F. Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood. 2005;105(7):2852–61.

    CAS  PubMed  Google Scholar 

  102. Barreiro O, Zamai M, Yáñez-Mó M, Tejera E, López-Romero P, Monk PN, Gratton E, Caiolfa VR, Sánchez-Madrid F. Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms. J Cell Biol. 2008;183(3):527–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  103. Gaillard PJ, Visser CC, Appeldoorn CC, Rip J. Targeted blood-to-brain drug delivery – 10 key development criteria. Curr Pharm Biotechnol. 2012;13(12):2328–39.

    CAS  PubMed  Google Scholar 

  104. Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, Kooij G, de Vries HE, Reijerkerk A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release. 2012;164(3):364–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Cell Biology and Immunology (MCBI), Neuroscience Campus, VU University Medical Center, 7057, Amsterdam, 1007MB, The Netherlands

    Mark R. Mizee, Gijs Kooij & Helga E. de Vries

Authors
  1. Mark R. Mizee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gijs Kooij
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helga E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helga E. de Vries .

Editor information

Editors and Affiliations

  1. Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA

    Phillip K. Peterson

  2. Department of Biochemistry Department of Molecular Biology, University of Miami School of Medicine, Miami, Florida, USA

    Michal Toborek

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mizee, M.R., Kooij, G., de Vries, H.E. (2014). Multiple Sclerosis: Impact on Functioning of the Blood–Brain Barrier. In: Peterson, P., Toborek, M. (eds) Neuroinflammation and Neurodegeneration. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1071-7_8

Download citation

Publish with us

Policies and ethics

Search

Navigation